192 related articles for article (PubMed ID: 20856813)
21. Disassociation of insulin action and Akt/FOXO signaling in skeletal muscle of older Akt-deficient mice.
Reynolds TH; Merrell E; Cinquino N; Gaugler M; Ng L
Am J Physiol Regul Integr Comp Physiol; 2012 Dec; 303(11):R1186-94. PubMed ID: 23100026
[TBL] [Abstract][Full Text] [Related]
22. Myostatin gene invalidation does not prevent skeletal muscle mass loss during experimental sepsis in mice.
Morel J; Pignard AS; Castells J; Allibert V; Hatimi L; Buhot B; Velarde M; Durieux AC; Freyssenet D
J Physiol; 2024 Jun; 602(12):2839-2854. PubMed ID: 38748517
[TBL] [Abstract][Full Text] [Related]
23. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2.
Peng XD; Xu PZ; Chen ML; Hahn-Windgassen A; Skeen J; Jacobs J; Sundararajan D; Chen WS; Crawford SE; Coleman KG; Hay N
Genes Dev; 2003 Jun; 17(11):1352-65. PubMed ID: 12782654
[TBL] [Abstract][Full Text] [Related]
24. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
[TBL] [Abstract][Full Text] [Related]
25. Connexin43 and zonula occludens-1 are targets of Akt in cardiomyocytes that correlate with cardiac contractile dysfunction in Akt deficient hearts.
Ock S; Lee WS; Kim HM; Park KS; Kim YK; Kook H; Park WJ; Lee TJ; Abel ED; Kim J
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1183-1191. PubMed ID: 29378301
[TBL] [Abstract][Full Text] [Related]
26. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
28. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
[TBL] [Abstract][Full Text] [Related]
29. AKT2 is the predominant AKT isoform expressed in human skeletal muscle.
Matheny RW; Geddis AV; Abdalla MN; Leandry LA; Ford M; McClung HL; Pasiakos SM
Physiol Rep; 2018 Mar; 6(6):e13652. PubMed ID: 29595878
[TBL] [Abstract][Full Text] [Related]
30. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
31. High-intensity muscle contraction-mediated increases in Akt1 and Akt2 phosphorylation do not contribute to mTORC1 activation and muscle protein synthesis.
Maruyama Y; Ikeda C; Wakabayashi K; Ato S; Ogasawara R
J Appl Physiol (1985); 2020 Apr; 128(4):830-837. PubMed ID: 32078465
[TBL] [Abstract][Full Text] [Related]
32. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.
Winbanks CE; Murphy KT; Bernardo BC; Qian H; Liu Y; Sepulveda PV; Beyer C; Hagg A; Thomson RE; Chen JL; Walton KL; Loveland KL; McMullen JR; Rodgers BD; Harrison CA; Lynch GS; Gregorevic P
Sci Transl Med; 2016 Jul; 8(348):348ra98. PubMed ID: 27440729
[TBL] [Abstract][Full Text] [Related]
33. Akt1 deficiency diminishes skeletal muscle hypertrophy by reducing satellite cell proliferation.
Moriya N; Miyazaki M
Am J Physiol Regul Integr Comp Physiol; 2018 May; 314(5):R741-R751. PubMed ID: 29443546
[TBL] [Abstract][Full Text] [Related]
34. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.
Relizani K; Mouisel E; Giannesini B; Hourdé C; Patel K; Morales Gonzalez S; Jülich K; Vignaud A; Piétri-Rouxel F; Fortin D; Garcia L; Blot S; Ritvos O; Bendahan D; Ferry A; Ventura-Clapier R; Schuelke M; Amthor H
Mol Ther; 2014 Aug; 22(8):1423-1433. PubMed ID: 24861054
[TBL] [Abstract][Full Text] [Related]
35. Role of Akt2 in contraction-stimulated cell signaling and glucose uptake in skeletal muscle.
Sakamoto K; Arnolds DE; Fujii N; Kramer HF; Hirshman MF; Goodyear LJ
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1031-7. PubMed ID: 16803855
[TBL] [Abstract][Full Text] [Related]
36. AKT2 regulates development and metabolic homeostasis via AMPK-depedent pathway in skeletal muscle.
Chen M; Ji C; Yang Q; Gao S; Peng Y; Li Z; Gao X; Li Y; Jiang N; Zhang Y; Bian X; Chen C; Zhang K; Sanchis D; Yan F; Ye J
Clin Sci (Lond); 2020 Sep; 134(17):2381-2398. PubMed ID: 32880392
[TBL] [Abstract][Full Text] [Related]
37. The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity.
Akpan I; Goncalves MD; Dhir R; Yin X; Pistilli EE; Bogdanovich S; Khurana TS; Ucran J; Lachey J; Ahima RS
Int J Obes (Lond); 2009 Nov; 33(11):1265-73. PubMed ID: 19668253
[TBL] [Abstract][Full Text] [Related]
38. Akt and Rac1 signaling are jointly required for insulin-stimulated glucose uptake in skeletal muscle and downregulated in insulin resistance.
Sylow L; Kleinert M; Pehmøller C; Prats C; Chiu TT; Klip A; Richter EA; Jensen TE
Cell Signal; 2014 Feb; 26(2):323-31. PubMed ID: 24216610
[TBL] [Abstract][Full Text] [Related]
39. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
40. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Lee SJ; Lehar A; Meir JU; Koch C; Morgan A; Warren LE; Rydzik R; Youngstrom DW; Chandok H; George J; Gogain J; Michaud M; Stoklasek TA; Liu Y; Germain-Lee EL
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23942-23951. PubMed ID: 32900939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
